

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>CURRY ROBERT E</u> (Last) (First) (Middle) <u>C/O THE SPROUT GROUP</u> <u>3000 SAND HILL ROAD, BLD 1, STE. 170</u> (Street) <u>MENLO PARK CA 94025</u> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 03/16/2004	3. Issuer Name and Ticker or Trading Symbol <u>XCYTE THERAPIES INC [XCYT]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year) 03/10/2004 6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date				
Convertible Promissory Note	03/19/2004 ⁽¹⁰⁾	03/19/2004	Common Stock 10,670	9.625	I	See Footnote ⁽¹⁾⁽²⁾
Series A Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock 478,466	5.225	I	See Footnote ⁽¹⁾⁽³⁾
Series B Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock 99,172	6.05	I	See Footnote ⁽¹⁾⁽⁴⁾
Series C Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock 207,805	9.185	I	See Footnote ⁽¹⁾⁽⁵⁾
Series D Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock 58,861	15.29	I	See Footnote ⁽¹⁾⁽⁶⁾
Series E Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock 64,741	15.29	I	See Footnote ⁽¹⁾⁽⁷⁾
Series F Convertible Preferred Stock	03/19/2004 ⁽¹¹⁾	03/19/2004	Common Stock 660	15.29	I	See Footnote ⁽¹⁾⁽⁸⁾
Common Stock Warrants (right to buy)	03/19/2004 ⁽¹²⁾	03/19/2004 ⁽¹³⁾	Common Stock 42,196	0.055	I	See Footnote ⁽¹⁾⁽⁹⁾

Explanation of Responses:

- 1. See Attachment
- 2. See Attachment
- 3. See Attachment
- 4. See Attachment
- 5. See Attachment
- 6. See Attachment
- 7. See Attachment
- 8. See Attachment
- 9. See Attachment
- 10. See Attachment
- 11. See Attachment
- 12. See Attachment
- 13. See Attachment

/s/ Joanna Lin Black, as Attorney-in-Fact for Robert L. Curry 03/16/2004

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

POWER OF ATTORNEY

Know all by these presents, that the undersigned hereby constitutes and appoints each of Kathi Cordova and Joanna Lin Black, signing singly, the undersigned (1) execute for and on behalf of the undersigned, in the undersigned's capacity as an officer, director and/or 10% stockholder of Xcyte Therapies, Inc. (the (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, 3, 4 or (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney-in-fact, may be of benefit to, in the undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform any and every act and thing whatsoever requisite, necessary and proper. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Forms 3, 4 or 5 with respect to the undersigned. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 4th day of March, 2004.

/s/Robert E. Curry

Signature

Robert E. Curry

Print Name

Attachment A
EXPLANATION TO RESPONSES:

Reporting Person Issuer Name and Ticker Symbol Statement for MM/DD/YY
Robert L. Curry/o The Sprout Group3000 Sand Hill RoadBuilding 1, Suite 170Menlo Park, CA 94025 Xcyte Therapies, Inc. (XCYT) 3/10/04

- (1) Sprout Capital VII, L.P. ("Sprout VII"), Sprout CEO Fund, L.P. ("Sprout CEO"), DLJ First ESC, L.P. ("ESC") and Sprout Plan Investors, L.P. ("Plan Investors")
e for its day-to-day management. DLJLBO makes all of the investment decisions on behalf of ESC. DLJ LBO Plans Management Corporation II ("DLJLBOII"), a Delaware co
- (2) Includes 213 shares of Common Stock, upon conversion of convertible promissory notes held of record by DLJ Capital Corporation, 1,066 shares of Common Stock,
- (3) Includes 9,569 shares of Series A Convertible Preferred Stock held of record by DLJ Capital Corporation., 47,846 shares of Series A Convertible Preferred Stock
- (4) Includes 1,983 shares of Series B Convertible Preferred Stock held of record by DLJ Capital Corporation., 9,917 shares of Series B Convertible Preferred Stock

Reporting Person Issuer Name and Ticker Symbol Statement for MM/DD/YY
Robert L. Curry/o The Sprout Group3000 Sand Hill RoadBuilding 1, Suite 170Menlo Park, CA 94025 Xcyte Therapies, Inc. (XCYT) 3/10/04

- (5) Includes 4,156 shares of Series C Convertible Preferred Stock held of record by DLJ Capital Corporation., 20,780 shares of Series C Convertible Preferred Stock
- (6) Includes 1,177 shares of Series D Convertible Preferred Stock held of record by DLJ Capital Corporation., 5,886 shares of Series D Convertible Preferred Stock
- (7) Includes 1,308 shares of Series E Convertible Preferred Stock held of record by DLJ Capital Corporation., 6,540 shares of Series E Convertible Preferred Stock
- (8) Includes 660 shares of Series F Convertible Preferred Stock held of record by Sprout CEO Fund, L.P. Dr. Curry disclaims beneficial ownership of shares held
- (9) Includes 843 shares of Common Stock issuable upon exercise of warrants held of record by DLJ Capital Corporation, 4,219 shares of Common Stock issuable upon
- (10) These convertible promissory notes will be converted in common stock upon the completion of the initial public offering ("IPO").
- (11) Immediately following the closing of the IPO of the Issuer's common stock, all outstanding shares of preferred stock will be converted into common stock of 1
- (12) This warrant will be exercised upon the closing of the IPO through a net exercise feature at the IPO price.
- (13) The warrant expires upon the closing of the IPO.